Alfred Sandrock, M.D., Ph.D., is a distinguished figure in the field of neuroscience and biotechnology, currently serving as the Chief Executive Officer, President, and Director at Voyager Therapeutics Inc. Dr. Sandrock's impressive career spans several decades, during which he has made significant contributions to the development of treatments for neurological disorders. He holds both a medical degree and a Ph.D. in neurobiology from the University of Pennsylvania, which provided him with a robust foundation in both clinical and research aspects of neuroscience. Before joining Voyager Therapeutics, Dr. Sandrock held a pivotal role at Biogen as the Executive Vice President of Research and Development and Chief Medical Officer. During his tenure at Biogen, he was instrumental in the development and approval of several groundbreaking therapies for multiple sclerosis, spinal muscular atrophy, and other neurological conditions. His leadership and strategic vision were key to advancing Biogen's pipeline and establishing the company as a leader in the neuroscience space. At Voyager Therapeutics, Dr. Sandrock continues to leverage his extensive experience and expertise to drive the company's mission of developing gene therapies for severe neurological diseases. Under his guidance, Voyager is focusing on innovative approaches to target the root causes of these disorders, aiming to bring transformative treatments to patients in need.